41.90
+1.40
(3.46%)
May 22 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 40.25 - 41.90 |
| 52 week | 36.00 - 58.00 |
| Open | 40.50 |
| Vol / Avg. | 21,715.00/8,396.00 |
| Mkt cap | 31.50M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.03* |
| Shares | 75.18M |
| Beta | - |
| Inst. own | - |
| *GBP |
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -66.78% | -57.14% |
| Return on average equity | -79.96% | -68.97% |
| Employees | 18 | - |
| Carbon Disclosure Rating | - | - |
Address
Southampton General Hospital South Block, Mailpoint 810, Level F Tremona Road
SOUTHAMPTON, SO16 6YD
United Kingdom - Map
+44-23-80512800 (Phone)
+44-23-80512800 (Fax)
SOUTHAMPTON, SO16 6YD
United Kingdom - Map
+44-23-80512800 (Phone)
+44-23-80512800 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Synairgen plc is a respiratory drug discovery and development company. The Company is specializing in respiratory diseases with a focus on asthma and chronic obstructive pulmonary disease (COPD) and influenza. Development on Synairgen�s inhaled IFN-b programme include SG003 Phase I study, SG004 Phase I study, Aerosol device and Pre-clinical influenza study. As of June 30, 2011, the Company held 100% interest in Synairgen Research Limited.
Officers and directors
| John Ward | Finance Director, Company Secretary, Executive Director | |
| Phillip Monk | Chief Scientific Officer, Executive Director | |
| Richard Marsden | Chief Executive Officer, Executive Director | |
| Simon Shaw | Non-Executive Chairman of the Board | |
| Iain Buchanan | Non-Executive Director | |
| Bruce Campbell | Non-Executive Director | |
| Paul Hugh Anthony Clegg | Non-Executive Director | |
| Stephen Holgate CBE | Non-Executive Director |